TORONTO--(BUSINESS WIRE)--CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, has submitted an application with the U.S. Food and Drug Administration (“FDA”) for clearance of its GUAVATM II ECG viewer technology.
